Keyphrases
C-Met
100%
Drug Resistance
100%
Fusion Protein
100%
B-Raf
100%
Mass Spectrometry
40%
MET Receptor
40%
MET Inhibitor
40%
Cancer Treatment
20%
Signaling Pathway
20%
Cell Growth
20%
Cancer Causes
20%
Recurrent Disease
20%
Motility
20%
Tumor Cells
20%
Small Molecules
20%
Phenotypic Change
20%
Proteomic Analysis
20%
Protein Level
20%
Canonical Pathway
20%
Target Molecule
20%
Anticancer Drugs
20%
Treatment Failure
20%
Tyrosine Kinase
20%
Cell Lysate
20%
Ingenuity Pathway Analysis
20%
Gene Copy number
20%
Treatment Conditions
20%
Quantitative Phosphoproteomics
20%
Phosphoproteomic Analysis
20%
Fusion Partner
20%
In Vitro Digestion
20%
Phosphoprotein Enrichment
20%
LC-mass Spectrometry
20%
LTQ-Orbitrap
20%
Chemical Labeling
20%
Gastric Carcinoma Cells
20%
Hydrophilic Interaction Liquid Chromatography (HILIC)
20%
NanoLC
20%
Transcriptomic Changes
20%
Orbitrap MS
20%
K-plex
20%
Isobaric
20%
Treatment Understanding
20%
Expression Profiling
20%
Phosphopeptide Enrichment
20%
Drug Resistance Mechanisms
20%
Bottom-up Mass Spectrometry
20%
Quantitative Mass Spectrometry
20%
Tandem Mass Tag
20%
Biochemistry, Genetics and Molecular Biology
Mass Spectrometry
100%
Fusion Protein
100%
Drug Resistance
100%
Eicosanoid Receptor
66%
Solution and Solubility
33%
Proteomics
33%
Cell Growth
33%
Tandem Mass Spectrometry
33%
Signal Transduction
33%
Phosphotransferase
33%
Kinase
33%
Receptor Tyrosine Kinase
33%
Small Molecule
33%
Fractionation
33%
Anticancer
33%
Cell Lysate
33%
Gene Dosage
33%
Phosphopeptide
33%
Phosphoprotein
33%
Phosphoproteomics
33%
Transcriptomics
33%
Hydrophilic Interaction Chromatography
33%
Tandem Mass Tag
33%
Chemical Labeling
33%